REG - Futura Medical PLC - Notice of AGM and availability of Annual Report

Futura MedicalAnnouncement

24/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240524:nRSX7407Pa&default-theme=true

RNS Number : 7407P  Futura Medical PLC  24 May 2024

24 May 2024

 

Futura Medical plc

("Futura" or the "Company")

Notice of AGM and availability of Annual Report

 

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon,
that specialises in the development and global commercialisation of
innovative and clinically proven sexual health products, today announces its
Annual General Meeting ("AGM") will be held at 10:00am on Thursday, 20 June
2024 at the offices of Liberum Capital Limited, Ropemaker Place, 25 Ropemaker
Street, London EC2Y 9LY.

 

If you wish to attend the meeting in person, please register your interest,
prior to 10:00am on Monday 17 June 2024, at
investor.relations@futuramedical.com
(mailto:investor.relations@futuramedical.com) .

 

Shareholders are asked to cast their vote as follows: (1) casting your proxy
vote online via the Link Investor Centre app or by accessing the web browser
at https://investorcentre.linkgroup.co.uk/Login/Login
(https://investorcentre.linkgroup.co.uk/Login/Login) and following the
instructions; or (2) in the case of CREST members, by utilising the CREST
electronic proxy appointment service; or (3) if you are an institutional
investor you may also be able to appoint a proxy electronically via the
Proxymity platform; or (4) requesting a hard copy form of proxy directly from
the registrars, Link Group. If you choose to attend the Annual General Meeting
in person instead of appointing the Chairman of the meeting as proxy, as we
strongly recommend, you will still be able to vote in person at the Annual
General Meeting.

 

If you are not attending the Annual General Meeting in person, your proxy vote
will need to be logged

by 10:00am on Tuesday 18 June 2024, as no online voting will take place
in-real time during the meeting itself.

 

The Board will make arrangements for shareholders to listen to proceedings
remotely should they wish to do so. You can request access by emailing:
investor.relations@futuramedical.com prior to 10:00 a.m. on 17 June 2024.
Shareholders will not get an opportunity to vote or ask questions or
participate in any other way during the call.

 

 

Annual Report

 

Futura's annual report and accounts for the year ended 31 December 2023 (the
"Annual Report") is available to shareholders as an electronic communication
pursuant to the Companies Act 2006 and is now available on the Company's
website www.futuramedical.com (http://www.futuramedical.com) , along with the
Notice of AGM.

 

Contacts:

 Futura Medical plc              James Barder               investor.relations@futuramedical.com

                          (mailto:Investor.relations@futuramedical.com)
                                 Chief Executive Officer

                          +44 (0)1483 685 670
                                 Angela Hildreth

                          www.futuramedical.com (http://www.futuramedical.com/)
                                 Finance Director and COO

 Liberum                         Phil Walker                +44 (0)20 3100 2000

 Nominated Adviser               Richard Lindley

 and Broker                      Nikhil Varghese

 Stifel Nicolaus Europe Limited  Alan Selby                 +44 (0)207 710 7600

 Joint Broker                    Ben Maddison

 Alma Strategic Communications   Rebecca Sanders-Hewett     +44 (0)20 3405 0205

                                 Sam Modlin                 futura@almastrategic.com

                                 Will Ellis Hancock

 

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon. Our core strength lies in our
research, development and commercialisation of topically delivered gel
formulations in sexual health products.

Eroxon, Futura's clinically proven lead product, has been developed for the
treatment of Erectile Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the counter and
helps men get an erection in ten minutes, addresses significant unmet needs
in the ED market.

ED impacts 1 in 5 men globally across all adult age brackets, with
approximately half of all men over 40 experiencing ED and 25% of all new
diagnoses being in men under 40.

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe. Eroxon has been nominated for a number
of healthcare industry awards and has won two to-date.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSBLGDUCUDDGSX